Abstract

The aim of this study was to evaluate the effects of two gamma‐amino butyric acid (GABA)a receptor antagonists on motor behavioral tasks in a pharmacological model of Parkinson disease (PD) in rodents. Ninety‐six Swiss mice received intraperitoneal injection of Haloperidol (1 mg/kg) to block dopaminergic receptors. GABAa receptors antagonists Bicuculline (1 and 5 mg/kg) and Flumazenil (3 and 6 mg/kg) were used for the assessment of the interaction among these neurotransmitters, in this PD model. The motor behavior of the animals was evaluated in the catalepsy test (30, 60, and 90 min after drugs application), through open field test (after 60 min) and trough functional gait assessment (after 60 min). Both Bicuculline and Flumazenil were able to partially reverse catalepsy induced by Haloperidol. In the open field test, Haloperidol reduced the number of horizontal and vertical exploration of the animals, which was not reversed trough application of GABAa antagonists. Furthermore, the functional gait assessment was not sensitive enough to detect motor changes in this animal model of PD. There is an interaction between dopamine and GABA in the basal ganglia and the blocking GABAa receptors may have therapeutic potential in the treatment of PD.

Highlights

  • Caused by loss of dopaminergic neurons in substantia nigra, Parkinson’s disease (PD) leads to a very well described disruption of extrapyramidal motor functions

  • Dopaminergic replacement is the main treatment in PD to relieve the neurotransmission symptoms on the alteration in nigrostriatal pathway (Jankovic 2002)

  • The PD pharmacological treatment is currently performed with dopamine agonists and Levodopa (L-dopa)

Read more

Summary

Introduction

Caused by loss of dopaminergic neurons in substantia nigra, Parkinson’s disease (PD) leads to a very well described disruption of extrapyramidal motor functions. The PD pharmacological treatment is currently performed with dopamine agonists and Levodopa (L-dopa). These drugs are quite effective in the early stages of the disease, treating neuromotor symptoms without altering the disease progression. It still causes several adverse effects such as nausea, vomiting, hypotension, and motor complications in the long term (Jenner 2003). It is necessary to develop new pharmacological approaches that are able to act in all stages of the disease, diminishing the risk of appearance of involuntary movements (Jenner 2003)

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.